Floatz logo

IMIPENEM

Malignant Solid Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

1411 Active assets in the Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

IMIPENEM is also rated in:

Critical IllnessDormant
BB
Indicative ·
65 / 100
View asset →
bacterial pneumoniaDormant
BB
Indicative ·
65 / 100
View asset →
cystic fibrosisDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →